Progranulin as a Potential Therapeutic Target in Immune-Mediated Diseases

Yue-Jiao Lan 1,2, Napoleon Bellua Sam 3, Ming-Han Cheng 1, Hai-Feng Pan 4,5, Jian Gao 1

1Pediatric Translational Medicine Institute, Shanghai Children’s Medical Center; School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 2The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 3Department of Medical Research and Innovation, School of Medicine, University for Development Studies, Tamale, Ghana; 4Department of Epidemiology & Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, People’s Republic of China; 5Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, People’s Republic of China

Correspondence: Jian Gao
Pediatric Translational Medicine Institute, Shanghai Children’s Medical Center; School of Medicine, Shanghai Jiao Tong University, Shanghai, 200120, People’s Republic of China
Email gaojian@scmc.com.cn; gaojianayfy@163.com
Hai-Feng Pan
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, 230032, People’s Republic of China
Email panhaifeng@ahmu.edu.cn

Abstract: Progranulin (PGRN), a secretory glycoprotein consisting of 593 amino acid residues, is a key actor and regulator of multiple system functions such as innate immune response and inflammation, as well as tissue regeneration. Recently, there is emerging evidence that PGRN is protective in the development of a variety of immune-mediated diseases, including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), type 1 diabetes mellitus (T1DM) and multiple sclerosis (MS) by regulating signaling pathways known to be critical for immunology, particularly the tumor necrosis factor alpha/TNF receptor (TNF-α/TNFRI) signaling pathway. Whereas, the role of PGRN in psoriasis, systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) is controversial. This review summarizes the immunological functions of PGRN and its role in the pathogenesis of several immune-mediated diseases, in order to provide new ideas for developing therapeutic strategies for these diseases.

Keywords: PGRN, TNF-α, TNFR, immune-mediated diseases, therapeutic

Introduction

The immune system has several fundamental functions, namely protecting against invasion by pathogenic micro-organisms, removing mutated somatic cells, and regulating the suitable immune system’s reaction intensity to antigenic stimuli. In relation to physiological and pathological conditions, the immune system is inseparable from the changes in inflammatory mechanisms. When the body is attacked by injury or pathogenic micro-organisms irritation, it is often accompanied by acute inflammation, a normal safeguarding response. However, uncontrolled inflammatory responses and sustained immune responses may result in immune system disorders such as rheumatoid arthritis (RA) and diabetes mellitus as well as inflammatory bowel disease (IBD). Although the release of cytokines for immunity and inflammation is crucial to the immune functions, hyper-function of cytokines such as tumor necrosis factor alpha (TNF-α) may damage host tissues, and its mobilization against self-targets causes the development of autoimmune disorders. TNF-α is at the top of the reaction of inflammatory cascade, the TNF-α/TNFRI signaling pathway coordinates a large number of inflammatory processes, and is pivotal for the occurrence and development of sundry inflammation-induced immune-mediated diseases. As a secreted molecule with some cytokine-like properties, progranulin (PGRN) is a unique ligand of TNF receptor (TNFR), which plays its anti-inflammatory action mainly through TNF Receptor 1 (TNFR1) and stimulus CD4+CD25+Foxp3+ regulatory T cells (Treg) activity by binding to TNF Receptor 2...
(TNFR2) to limit the role of TNF-α in some immune-mediated diseases, such as RA and IBD. In addition to the effect on maintaining Treg function, PGRN deficiency also interferes with the immune response of other T cells such as T-helper 1 (Th1) and T-helper 17 (Th17), PGRN influences Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway to reduce cell response of Th1 and Th17 and cytokines secretion in vitro and in vivo. PGRN is cleaved by elastase to yield discrete fragments named Granulin (GRN) in vitro. The GRN acts as an essential role in defense infection in the innate immunity. The innate immunity belongs to the immune system, has been considered as the first powerful defense against the invasion of various pathogenic microorganisms and foreign bodies. GRN assists in recruiting of CpG oligonucleotides (CpG-ODNs) in macrophages by binding to Toll-like receptor 9 (TLR9), reinforcing innate immunity against bacteria invasion. For example, PGRN can exacerbate SLE severity by enhancing TLR9 signaling. Therefore, PGRN may be the primary regulators of inflammation and autoimmunity and may serve as biomarkers as well as indicating a promising and novel therapeutic concept to treat diverse inflammatory immune-mediated diseases. In this review, we will briefly summarize the immunological functions of PGRN and its role in immune-mediated diseases, and highlight its potential as a therapeutic target for these diseases.

**Immunological Functions of PGRN**

PGRN is similarly known as proepithelin (PEPI), PC-cell-derived growth factor (PCDGIF), Granulin-epithelin precursor (GEP), and GP88. It is a protein of 12 coding exons transcribed from the gene Granulin (GRN), located on the human chromosome 17q21.32. The architecture of PGRN is a domain of six parallel stacks of β-hairpins linked by six disulfide bridges. The disulfide bridges are crucial to maintain appropriate protein folding and unique confirmation. The 68.5 kDa relative molecular mass PGRN may be lysed by a variety of proteolytic enzymes. Expression of the PGRN may be discovered in rapid proliferating cells, which comprise epithelial cells, immune cells, macrophages, neuronal cells, adipocytes, fibroblastic cell, and chondrocytes (Figure 1).

PGRN not only plays a fundamental role in tumorigenesis, but also is a vital immunomodulator. In relation to disease types and key signaling pathways, PGRN functions as a double-edged sword in playing the pro-
inflammatory role and anti-inflammatory role in immune-mediated diseases. Furthermore, PGRN may be an effective bone morphogenetic protein that participates in the development of related immune diseases involving joints or arthritis complications such as systemic lupus erythematosus (SLE), RA and psoriasis. Nevertheless, the proper function regulated by PGRN may vary relying on the pathology and physiology context of the disease (Figure 2).

**Inflammation**

During inflammation, neutrophils and macrophages release proteases such as matrix metalloproteinase-9 (MMP-9), MMP-12, MMP-14, neutrophil elastase, and proteinase 3 (PRTN3) in which PGRN may be subjected to degradation by MMP-9, MMP-12, MMP-14, neutrophil elastase, and PRTN3. Attrin: an engineered protein consists of the FAC domain of PGRN.

**Anti-Inflammation**

Conversely, the protection of anti-inflammatory properties of PGRN depends on its combined proteins such as the secretory leukocyte protease inhibitor and apolipoprotein A1, which bind with full-length PGRN against protease hydrolysis. Compared with its pro-inflammatory mechanism, its inhibitory effect on inflammation has received greater attention. The central anti-inflammatory role of PGRN is to mediate the TNF-α/TNFR signaling pathway through binding to the slender cysteine-rich domain 2 (CRD2) and CRD3 of TNFR1 and TNFR2 extracellular region. Moreover, the binding affinity of PGRN and TNFR1 is equivalent to that of TNF-α, while the binding affinity of PGRN and TNFR2 is nearly 600 times that of TNF-α. Among them, PGRN binds to TNFR1 and activates extracellular regulated protein kinase 1 and 2 (ERK1/2) and phosphatidylinositol 3 kinases/protein kinase B (PI3K/AKT) pathways to competitively interfere with activation of TNF-α mediated nuclear factor of kappa (NF-κB) inflammatory pathway. Besides, PGRN and its derivative Attrin, directly combine to death receptor 3 (DR3), the highest homology to TNFR, to block the binding of DR3 and TNF-like ligand 1A (TL1A) to play a supplementary anti-inflammatory role. Additionally, recent findings suggested that cytokine IL-10 with anti-inflammatory properties predominantly from Treg cells, was a crucial mediator in PGRN-mediated anti-inflammation. Again, PGRN expands and activates...

**Figure 1** The structure, source and intervention of PGRN in the autoimmune system. The architecture of PGRN is made up of 7.5 cysteine-rich motif and mainly distributes in various cell lines. Some microRNAs specifically stimulate or inhibit PGRN activation. The SLPI and apolipoprotein A1 can bind to it to protect it against proteolytic degradation by MMP-9, MMP-12, MMP-14, neutrophil elastase, and PRTN3. Attrin: an engineered protein consists of the FAC domain of PGRN.

**Abbreviations:** PGRN, Progranulin; GRN, Granulin; HDAC4, histone deacetylase 4; SLPI, secretory leukocyte protease inhibitor; MMP-9, matrix metalloproteinase-9; PRTN3, proteinase 3.
Treg cells and production of IL-10 via stimulating phosphorylation of c-Jun N-terminal kinase (JNK). These events depend on TNFR2, but did not rely on PGRN-mediated activation of ERK and PI3K pathways. Moreover, forkhead box protein O4/signal transducer and activator of transcription 3; Treg, regulatory T cells; Ikk, I kappaB kinase; IrB, irbesartan; PRTN3, proteinase 3; MMP-9, matrix metalloproteinase-9; IL-8, interleukin-8; ERK1/2, extracellular regulated protein kinase 1 and 2; PI3K, phosphatidylinositol 3 kinases; AKT, protein kinase B; NF-κB, nuclear factor of kappa; Tregs, regulatory T cells; ADAMTS-7, A disintegrin and metalloproteinase with thrombospondin motifs 7; ADAMTS-12, A disintegrin and metalloproteinase with thrombospondin motifs 12; COMP, cartilage oligomeric matrix protein; TLK9, Toll-like receptor 9; DR3, death receptor 3; TL1A, TNF-like ligand 1A; IL-8, interleukin-8; MS, multiple sclerosis.

**Induce Chondrogenesis and Cartilage Repair**

In addition to regulating inflammation in immune diseases, another critical protective role of PGRN is as a potent stimulator in response to cartilage differentiation to participate in the development of related immune diseases involving joints or arthritis complications such as RA and T1DM. Recent data show that PGRN is highly increased in the process of cartilage formation...
in vitro and is actively involved in the whole chondrogenesis.48,49 The role of PGRN in cartilage development and cartilage repair is regulated by BMP2.50 PGRN reduces cartilage degradation and produces bone protection determined by NF-κB signal and its related target gene, especially JunB transcription factor. Moreover, PGRN may inhibit cartilage loss bone resorption mediated by NF-κB pathway in a TNFR1-dependent manner.51 PGRN is also directly associated with cartilage oligomeric matrix protein (COMP) and chondrocyte proliferation.48 COMP is a prominent non-collagenous component of cartilage that exerts a stabilizing effect in the cartilage matrix and degrades severely in joints or arthritis complications.52,53 Degradation of COMP evoked by TNF-α may be rescued by PGRN.54 PGRN not only inhibits TNF-induced A disintegrin and metalloproteinase with thrombospondin motifs 7/A disintegrin and metalloproteinase with thrombospondin motifs 12 (ADAMTS-7/12) expression, but also interferes with the degradation of COMP by ADAMTS-7/ADAMTS-12,55–57 and probably play a central role in the prevention of articular cartilage destruction in arthritis.58

**Regulation of Toll-Like Receptor 9 (TLR9) Signaling Pathway**

GRN decomposed from PGRN acts as a soluble cofactor in the process of TLR9 signaling induced by oligonucleotide CpG-DNA.59,60 Concretely, when PGRN is cleaved into GRN in tissues by elastase, GRN not only acts as a reinforcing agent for a combination between Cpg-ODNs and TLR9, but also heavily promotes Cpg-ODNs delivery to the localization of TLR9 like endolysosomal compartments.6 In addition to the vital role of TLR9 in bacterial defense mentioned above, TLR9 also regulates NF-κB nuclear translocation61–65 which is critical for inflammatory cytokine production and involved in autophagy in many immune-mediated diseases such as RA.66 However, whether PGRN may mediate TLR9 signaling pathway in RA has not been reported. What is known at present is PGRN may act as an efficient biological marker for SLE activity and could be active in the pathogenesis and treatment of SLE partly through enhancement of TLR9 signaling.67 Further effort is still required to determine more precise mechanisms of the relationship between PGRN and TLR9 in human autoimmune disorders.

**PGRN in Immune-Mediated Diseases**

Immune-mediated diseases often result from failing to distinguish self from oneself,68 which is characterized by abnormalities in function of immune system and destructed tissues.59 Using biological agents to modify specific inflammatory and effector pathways is a promising therapeutic strategy in treating immune-mediated diseases. The agents of blocking TNF-α were approved firstly for therapeutic drugs, and since then drugs for certain autoimmune disorders have been developed. Although the treatment interrupts TNF-α individual continuous progression, the long-term prognoses are not satisfactory for most patients due to its serious side effects. Thus, there is an urgent need to explore novel therapeutic targets and strategies for clinical use. In recent years, emerging evidence has indicated that PGRN may play a role in the etiology and progression of these, including RA, SLE, SSc, IBD, psoriasis, type 1 diabetes mellitus (T1DM) and MS (Table 1).

**PGRN in Rheumatoid Arthritis**

RA, the universal autoimmune disease, is caused by persistent inflammation in the synovial joints, which ultimately leads to bone damage as well as disability.1 The function of inflammatory cytokines such as TNF-α, IL-8, IL-1b and IL-6 in the pathogenesis of RA has been implicated.70,71 PGRN is an antagonist of endogenous TNF-α, which plays an indispensable role in RA.72,73 To examine the exerted effect of endogenous PGRN in the process of inflammation in vivo, researchers pay attention to the investigation of the clinical and histopathological characteristics of PGRN7/7 mice model accompanied by collagen-induced arthritis (CIA), and found PGRN null mice are more susceptible to collagen-induced RA which led to a higher RA incidence and more bone and joint destruction than their control littermates, which reverted following the introduction of PGRN.18 Additionally, Tang et al. proved that recombinant PGRN administration improved CIA, significantly alleviating the disease severity and inflammatory arthritis mouse models induced by TNF-α transgene.5 In RA patients, Chen et al. further showed that the serum PGRN levels were up-regulated.74–76 Using biological agents to modify specific inflammatory and effector pathways is a promising therapeutic strategy in treating immune-mediated diseases. The agents of blocking TNF-α were approved firstly for therapeutic drugs, and since then drugs for certain autoimmune disorders have been developed. Although the treatment interrupts TNF-α individual continuous progression, the long-term prognoses are not satisfactory for most patients due to its serious side effects. Thus, there is an urgent need to explore novel therapeutic targets and strategies for clinical use. In recent years, emerging evidence has indicated that PGRN may play a role in the etiology and progression of these, including RA, SLE, SSc, IBD, psoriasis, type 1 diabetes mellitus (T1DM) and MS (Table 1).
differentiation model of mesenchymal stem cell line C2C12, PGRN alleviates the degree of TNF-α preventing osteoblast differentiation and plays a protective role in differentiation of osteoblast under inflammatory conditions. Furthermore, COMP degradation induced by TNF-α may be rescued by PGRN.54 Altogether, PGRN may

<table>
<thead>
<tr>
<th>Diseases</th>
<th>Subjects</th>
<th>Links to PGRN</th>
<th>Year</th>
<th>Author</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA</td>
<td>PGRN−/− C57BL/6 mice</td>
<td>PGRN−/− mice are highly susceptible to CIA, PGRN inhibit TNF-α-mediated activation of NF-κB and MAPK signaling.</td>
<td>2011</td>
<td>Tang et al.</td>
<td>[5]</td>
</tr>
<tr>
<td>RA patients</td>
<td>The concentrations of serum PGRN in RA were found to be significantly higher than control subjects.</td>
<td>2014</td>
<td>Yamamoto et al.</td>
<td>[72]</td>
<td></td>
</tr>
<tr>
<td>PGRN−/− B6 mice</td>
<td>PGRN inhibits expression and release of chemokines CXCL9 and CXCL10 in a TNFR1 dependent manner.</td>
<td>2016</td>
<td>Mundra et al.</td>
<td>[47]</td>
<td></td>
</tr>
<tr>
<td>RA patients</td>
<td>Serum PGRN elevated in RA patients, reflecting high disease activity.</td>
<td>2016</td>
<td>Chen et al.</td>
<td>[40]</td>
<td></td>
</tr>
<tr>
<td>RA patients</td>
<td>PGRN rescued miR-138 inhibitor-attenuated inflammatory cytokines release of FLS cells.</td>
<td>2019</td>
<td>Shao et al.</td>
<td>[70]</td>
<td></td>
</tr>
<tr>
<td>SLE</td>
<td>SLE patients</td>
<td>PGRN upregulated in serum of SLE, correlated with the serum IL-6 levels.</td>
<td>2012</td>
<td>Tanaka et al.</td>
<td>[67]</td>
</tr>
<tr>
<td>SLE patients</td>
<td>PGRN is up-regulated in the SLE patients and is correlated with pro-inflammatory cytokines and anti-dsDNA antibody.</td>
<td>2013</td>
<td>Qiu et al.</td>
<td>[76]</td>
<td></td>
</tr>
<tr>
<td>SLE Patients, PGRN−/− mice</td>
<td>PGRN levels are elevated in SLE patients, PGRN promotes tissue damage in SLE and exerts proinflammatory functions.</td>
<td>2020</td>
<td>Jing et al.</td>
<td>[12]</td>
<td></td>
</tr>
<tr>
<td>SSc</td>
<td>LSC patients, Human dermal fibroblasts</td>
<td>PGRN upregulated in LSC patients. PGRN expression regulated by constitutive activation of c-Abl/PKC-d/Fli1 pathway.</td>
<td>2018</td>
<td>Miyagawa et al.</td>
<td>[81]</td>
</tr>
<tr>
<td>SSc Patients</td>
<td>The expression of PGRN was increased in serum from SSc patients and in skin.</td>
<td>2019</td>
<td>Yang et al.</td>
<td>[77]</td>
<td></td>
</tr>
<tr>
<td>C57BL/6 mice</td>
<td>Overexpression of PGRN in SSc stimulates TGF-β/Smad3 signaling via upregulation of TβRI mouse model.</td>
<td>2019</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IBD</td>
<td>IBD patients, and mice</td>
<td>Elevated levels of PGRN were found in colitis samples from human IBD patients and mouse colitis models.</td>
<td>2014</td>
<td>Wei et al.</td>
<td>[6]</td>
</tr>
<tr>
<td>IBD patients</td>
<td>Upregulated PGRN-Abs participate in the pathogenesis of the seropositive subgroup of patients with IBDs by their neutralizing effect on the plasma level of secreted anti-inflammatory PGRN.</td>
<td>2014</td>
<td>Thurner et al.</td>
<td>[87]</td>
<td></td>
</tr>
<tr>
<td>Psoriasis</td>
<td>Psoriasis patients, PGRN−/− C57BL/6 mice</td>
<td>PGRN upregulated in psoriasis serum, PGRN enhanced inflammatory response to TPA in the skin, decreased percentages of Treg cells.</td>
<td>2015</td>
<td>Huang et al.</td>
<td>[90]</td>
</tr>
<tr>
<td>Psoriasis patients, PGRN−/− mice</td>
<td>Elevated levels of PGRN were found in colitis samples from human IBD patients and mouse colitis models in comparison to the corresponding controls.</td>
<td>2019</td>
<td>Farag et al.</td>
<td>[25]</td>
<td></td>
</tr>
<tr>
<td>MS</td>
<td>MS patients</td>
<td>PGRN is strongly expressed in MS brains.</td>
<td>2011</td>
<td>Vercellino et al.</td>
<td>[32]</td>
</tr>
<tr>
<td>T1DM</td>
<td>Mice</td>
<td>PGRN promoted impaired fracture healing in mouse diabetic fracture models.</td>
<td>2020</td>
<td>Wei et al.</td>
<td>[51]</td>
</tr>
</tbody>
</table>

Abbreviations: RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; IBD, inflammatory bowel disease; T1DM, type 1 diabetes mellitus; MS, multiple sclerosis; PBMC, peripheral blood mononuclear cell; CIA, collagen-induced arthritis; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor of kappa; TNFR1, TNF Receptor 1; FLS, Fibroblast-like synoviocytes; anti-dsDNA, anti-double-stranded DNA antibody; LSC, localized scleroderma; PKC-d, protein kinase C-delta; Fli1, Transcription factor Friend leukemia virus integration 1; TβRI, TGF-β receptor I; TPA, 12-O-tetradecanoylphorbol 13-acetate; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells.
inhibit TNF-mediated neutrophil activation and cartilage degradation and targeted intervention for PGRN may be an innovative therapy for the treatment of RA in the clinics.

**PGRN in Systemic Lupus Erythematosus**

SLE is a prototypic systemic inflammatory autoimmune disease resulting from autoantibodies production, auto-reactive T cells that cause tissue, organ damage, and deposition of immune complexes. The serum PGRN of SLE patients was higher compared with that of healthy controls. Serum PGRN levels are considerably associated with the activity of SLE clinical symptoms such as SLE Disease Activity Index and anti-double-stranded DNA antibody (anti-dsDNA) titers, and also correlates inversely with CH50, C3, and C4 levels which are associated with SLE severity and kidney injury. Moreover, the level of serum PGRN was markedly decreased following the successful SLE treatment. Furthermore, increased PGRN levels were positively correlated with the severity of pristane-induced murine model of SLE. Compared with WT SLE mice, tissue injuries significantly alleviated and autoantibody presence including anti-dsDNA and anti-ribosomal protein P0 basically reduced in PGRN-deficient (PGRN−/−) SLE mice. It is worth noting that destroyed T cell homeostasis is regarded as the significant pathological effect of SLE, associated studies have shown that PGRN could regulate immune responses of T lymphocyte mediation, because PGRN−/− SLE mice have lower levels of Th1 and Th17 levels and higher levels of Th2 and Treg cells than WT mice in the spleens, leading to inflammatory cytokines significantly decreasing such as Interferon gamma (IFN-γ) and interleukin-17A (IL-17A) and anti-inflammatory cytokines of IL-4 and IL-10 increasing. However, the above conclusion is contrary to the fact that PGRN can promote the differentiation of CD4+T cells into Tregs. The contradictory findings imply that the manner of PGRN regulating T cell functions differs in diverse disease states. Nevertheless, further studies are needed to examine the exact role regulated by PGRN in SLE.

Mechanically, PGRN might be an efficient disease activity index participating in the SLE pathogenesis partly by reinforcing the TLR9 signaling and the serum PGRN levels evidently and correlating with the serum IL-6 expression; CpG-B stimulated the PBMCs products of IL-6, which was upregulated by application of the recombinant human progranulin (rhPGRN). From the therapeutic perspective, it has been shown that the PGRN levels decreased after administration of large doses of prednisone. Prednisone is one of the glucocorticoids (GCs) and is generally acknowledged as an anti-inflammatory immunosuppressant. Therefore, it is not possible to fully establish that PGRN promotes the development of SLE based on the existing literature, and further studies are needed to refine the specific mechanism of PGRN on this disease.

**PGRN in Systemic Sclerosis**

SSc, also known as scleroderma, is an autoimmune fibrotic disease featured with the loss of control and sustained activation of fibroblasts, leading to excessive accumulation of collagen mainly including collagen type I (COL1) and (COL3), skin thickening, and differentiation of fibroblasts into myofibroblasts following an increase in α-smooth muscle actin (α-SMA). SSc loosely consists of two entirely different clinical classifications: systemic sclerosis (SSc) and localized scleroderma (LSC). Present literature has observed a distinct increment in PGRN in vivo and in vitro. Yang et al. have discovered a significant increment in the serum PGRN level in SSc patients. Results from immunohistology and RT-qPCR displayed that mRNA and protein of PGRN was also significantly elevated in the lesional skin from the scleroderma mouse model of BLM-induced manner. At the same time, their experiment on PGRN+/− mice further showed both attenuation of dermal fibrosis and amelioration of lesion myofibroblasts differentiation. Downregulation of TGF-β receptor 1 (TβR1) and p-Smad3 may account for the reduced severity degree of skin sclerosis in PGRN−/− mice, following corresponding diminution of connective tissue growth factor (CTGF), which is a downstream target gene of p-Smad3 in skin lesion. Conversely, impaired TβR I and p-Smad3 level could be significantly reversed by exogenous PGRN in mice dermal fibroblasts.

Additionally, in BLM-treated mice, Miyagawa et al. indicated that LSC dermal fibroblasts shared the Transcription factor Friend leukemia virus integration 1 (Fli1) deficiency and PGRN-dependent profibrotic actions with SSc dermal fibroblasts. Also, deleted Fli-1 transcription factor in SSc was found to cause the increase of PGRN expression through directly binding to the GRN promoter region to repress PGRN production. In vitro, the activated c-Abl/protein kinase C-δ/Fli1 (c-Abl/PKC-d/Fli1) pathway partly results in PGRN overproduction, which might help dermal fibroblasts counteract the partial anti-fibrotic effect of TNF-α. Given that the TNF-α roles in fibrosis are
a double-edged sword in vitro and in vivo, it is not possible to confirm whether PGRN displayed the similarity function and further investigations are needed to explore the exact molecular mechanisms of PGRN in SSc.

**PGRN in Inflammatory Bowel Disease**

IBD often presents as chronic relapsing intestinal inflammation, which encompasses two distinct diseases according to the clinical, histopathological, and pathogenetic characteristics, namely ulcerative colitis (UC) and Crohn’s disease (CD). In both diseases, innate and adaptive immune function changes are ultimately accompanied by increase of proinflammatory cytokine levels such as TNF-α, IL-6, IL-1β. Though the specific etiology of IBD remains unclear, with our understanding of IBD advancing in recent years, it has been shown that PGRN exerts a crucial role in mucosal inflammatory response and damage, and its effect has been confirmed in both IBD patients and mouse experimental colitis models. Wei et al. tested PGRN−/− mice and saw that they developed more severe colitis in comparison to the wild-control mice in the colitis model induced by chemical material such as dextran sulfate sodium (DSS) and trinitrobenzene sulfonic acid (TNBS). Also, lack of PGRN signaling in CD41 T cells intensifies experimental colitis. However, recombinant PGRN improves colitis syndrome. In addition, TNFR2 and IL-10 signaling are crucial to protective action of PGRN in IBD. Similarly, in addition to PGRN, neutralizing autoantibodies against PGRN (PGRN-Abs) also act on the serum of patients with multiple autoimmune disorders, particularly IBD. PGRN-Abs detected in 16.31% of CD patients and in 21.13% of UC patients demonstrated considerable effects of neutralizing PGRN levels in plasma. PGRN-Abs also showed a pro-inflammatory effect in IBD. Collectively, these studies show that PGRN is a crucial mediator of intestinal homeostasis, which dysregulated will aggravate intestinal inflammation during colitis. The protective action of PGRN in IBD principally relies on the TNFR2-mediated IL-10 signaling pathway. These findings describe not only the significant anti-inflammatory role of PGRN in vivo but also provide a novel strategy for PGRN and its derivatives in the treatment of intestinal inflammation.

**PGRN in Psoriasis**

Psoriasis is a genetic immune-mediated inflammatory skin disease that is often accompanied by hyperproliferation of the epidermal skin and a change of various vascular properties in the dermal layer. Increasing evidence has indicated that PGRN plays a critical role in psoriasis. Serum PGRN levels are dramatically incremented in psoriasis patients and PGRN were also found to be significantly increased in the psoriasis-like lesions of 12-O-tetradecanoylphorbol 13-acetate (TPA)-treated WT mice. Surprisingly, PGRN−/− mice were sensitive to TPA-induced psoriasis-like inflammation. PGRN may protect the skin from the exaggerated psoriasis-like inflammatory response by promoting Treg cells differentiating and recruiting at the site of inflammation. Additionally, Tian et al. investigated that PGRN was evidently expressed highly in inflammatory HaCaT cells and overexpression of PGRN inhibits the TNF-α-induced inflammation in keratinocytes and negatively regulates the production of inflammatory factors interleukin-1beta (IL-1β), interleukin 6 (IL-6), cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOs), and monocyte chemoattractant protein-1 (MCP-1) and positively mediates autophagy through the Wnt/β-catenin signaling pathway.

Although PGRN overexpression may be used as a potential immunotherapeutic option for psoriasis management programs, there are also studies suggesting that PGRN is considered as a pro-inflammatory cytokine in the pathogenesis of psoriasis. In the first instance, serum PGRN/TNF-α ratio was found to be negatively correlated with disease severity and also, Farag et al. identified that PGRN shifted from the circulation to the skin may be involved in the inflammatory response of keratinocytes at the tissue level in psoriasis by reducing the expression of β-catenin in psoriasis. This discrepancy may be attributed to the use of different methods. Some focused on the correlation of PGRN serum level, others depend on the expression of PGRN tissue.

**Other Immune-Mediated Diseases**

Apart from the disorders mentioned in the above immune-mediated diseases, PGRN has also been proved to be actively involved in the etiology of several other immune-mediated diseases, such as T1DM and MS and to play a protective role in both diseases.

T1DM is a major subtype of diabetes, which features islet β cells being destroyed in the pancreas caused by factors of heredity and environment, and patients with diabetes are often accompanied by an evidently increased risk of fracture and poor fracture healing. Studies on the role of PGRN in T1MD mainly focused on the diabetic bone healing process. Wei et al. employed multiple models...
of diabetic fracture and found that the PGRN−/− mice showed more severe delayed diabetic bone healing than controls. They also utilized recombinant PGRN, which may also promote diabetic fracture healing through accelerating callus formation and transformation of cartilage to bone. Under the diabetic condition, PGRN not only reduced the transcriptional levels of pro-inflammatory markers, including IL-1β, nitric oxide synthase-2 (NOS2), and COX-2 but also significantly promoted the levels of chondrogenic marker genes such as type II collagen and aggrecan. Mechanically, the effects of PGRN in promoting the diabetic fracture healing is possibly through binding to TNFRI to inhibit TNF-α-mediated inflammatory and bone erosion, and activating the Akt, ERK1/2, and mTOR signaling to accelerate formation of callus and promotion of callus transfer into new bone.51

With regards to MS, it is a chronic, predominantly autoimmune disease characterized by injury of the central nervous system (CNS), frequently resulting in neurological disability in young adults globally.92,93 PGRN is highly expressed in active demyelinating lesions by macrophages/microglia and in the normal appearing white matter (NAWM) by activated microglia; concentrations of MS PGRN cerebrospinal fluid (CSF) are correspondingly elevated in the case of activation of enhanced macrophage/microglia during progressive and recurrent MS. PGRN might protect against neuroinflammation in MS brains, downregulating the degree of injury of diverse neuronal cell populations induced by noxious stimuli.94 However, elevated CSF concentration of PGRN seems not specific to MS, but a common feature of CNS inflammation.

**PGRN as a Promising Therapeutic Target for Immune-Mediated Diseases**

PGRN, a double-edged sword, plays a pro-inflammatory or anti-inflammatory role in response to the different characteristics of its immune system diseases and targeted PGRN has promise as a potential approach for immune-mediated diseases. Understanding the intrinsic mechanisms driving PGRN and striving to find and develop reagents that specifically stimulate PGRN activation, inhibit its fragmentation or development of PGRN derivatives, may open an avenue to novel therapeutic options for immune-mediated diseases (Figure 1).9

Few studies have been done on several immune-mediated diseases by affecting the activity of PGRN. Understanding the molecules or pathways required for PGRN activation/inhibition is the first step in finding possible intervention targets. Given posttranslational modification, as a novel post-transcriptional regulator in mediating PGRN expression, microRNA-29b (miR-29b) binds directly to the human PGRN (hpGRN) to regulate the endogenous hpGRN expression through its 3’ untranslated region (3’UTR).95 Moreover, miR-29b-3p (3p means 3 prime end of the hairpin) facilitates chondrocyte apoptosis and aggravates the process of osteoarthritis by inhibiting PGRN.96 MiR-34b-5p inhibition has to be proved to activate PGRN that ameliorates inflammation.97 miR-138 activates PGRN to promote RA via regulating HDAC4.70 Similarly, down-regulation of sortilin 1 (SORT1) expression is a pivotal mechanism of PGRN elevation and a prospective target for PGRN to promote arthritis and other diseases, as indicated by PGRN KO mice phenotype.98 As for the protection of PGRN from proteolytic degradation, some proteins, such as the secretory leukocyte protease inhibitor (SLPI) and apolipoprotein A1 can bind to it to protect it against proteolytic degradation.34 Besides, an engineered protein consisted of the FAC domain of PGRN was constructed, which retains comparable TNFR binding affinity of PGRN referred as Atsttrin. More importantly, Atsttrin surpasses PGRN in delaying the degree of inflammation and in reducing mice susceptibility to collagen-induced arthritis RA in vivo,5 and Atsttrin-mediated mesenchymal stem cells joint therapy guard against osteoarthritis progress in a surgically induced murine osteoarthritis model.99 Additionally, Atsttrin lacks the carcinogenic activity of PGRN,100,101 which has attracted more attention, and the composition of Atsttrin prevents it from being digested by a single particle unit. Even at extremely high doses, no cytotoxicity or lethality associated with Atsttrin was observed. In terms of pharmacokinetics, Atsttrin is well absorbed after intraperitoneal administration, showing high stability, and its half-life is significantly longer compared with PGRN, so the application of Atsttrin gets more and more attention. Recombinant PGRN can also reduce the severity of the disease in collagen antibody induction, collagen induction, and TNF-α transgenic inflammatory arthritis mouse models. Collectively, studying the mechanism of PGRN in immune-mediated diseases and striving to develop specific PGRN-activated agents may provide directions for the development of drugs for immune-mediated diseases.

**Conclusion**

A solid basis of data from in vitro and in vivo models is accumulating to clarify the molecular mechanisms of PGRN in autoimmune disease. Particularly, the regulation of TNF-α/
TNF by PGRN is seen to have been characterized in detail, and the targeted PGRN may have some advantages compared with the existing TNF-α inhibitors. However, much remains to be explored about unresolved questions of PGRN in immune-mediated diseases. Firstly, the PGRN plays an essential role in immune-mediated diseases mainly as an extracellular protein and mediates the folding and transportation of its multiple binding partners in neurological diseases mainly as an intracellular protein. For example, PGRN binds to the soluble lysosomal protein, particularly Prosaposin (PSAP), participating in neurological disorders such as frontotemporal lobar degeneration (FTLD). However, extracellular PGRN binding to membrane receptors mediates PGRN uptake and regulates intracellular PGRN levels; whether intracellular PGRN participates in the occurrence of immune diseases and extracellular and intracellular PGRN exert functions that are integrated or completely independent remain to be clarified. Secondly, many studies have investigated the expression of PGRN in immune-mediated diseases, but the results are contradictory or incomplete. Finally, in addition to acting on TNFR, TLR9, and DR3 receptors, PGRN has also been shown to be involved in the regulation of the Notch receptor and Eph receptor A2 (EphA2), which also affect the function of the immune system, such as Notch1-4 is abnormally expressed in RA synovial cells, NF-κB-related pro-inflammatory activities in SLE M2b macrophages partly stimulated by Notch1 and EphA2 is a potential target for RA. Whether the relationship is indirect or direct between Notch/EphA2 and PGRN remains to be determined. In recent years, there is growing interest in the efforts to develop PGRN targeting treatments to overcome the current bottlenecks and also an urgent need to explore more precise actions of PGRN and GRN, especially in human systems and in host defense in order to comprehensively explore the role of PGRN in immune-mediated diseases.

Abbreviations
PGRN, Progranulin; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; IBD, inflammatory bowel disease; T1DM, type 1 diabetes mellitus; MS, multiple sclerosis; TNF-α, tumor necrosis factor alpha; TNFR, TNF receptor; TNFR1, TNF Receptor 1; Treg, regulatory T cells; Th1, T-helper 1; Th17, T-helper 17; JAK, Janus kinase; STAT, signal transducer and activator of transcription; Cpg-ODNs, CpG oligonucleotides; TLR9, Toll-like receptor 9; PEPI, proepithelin; PCDGF, PC-cell-derived growth factor; GEP, Granulin-epithelin precursor; MMP-9, matrix metalloproteinase-9; PRTN3, proteasine 3; CRD2, cysteine-rich domain 2; ERK1/2, extracellular regulated protein kinase 1 and 2; PI3K, phosphatidylinositol 3 kinases; AKT, protein kinase B; NF-κB, nuclear factor of kappa; DR3, death receptor 3; TL1A, TNF-like ligand 1A; JNK, c-Jun N-terminal kinase; FOXO4, forkhead box protein O4; STAT3, signal transducer and activator of transcription 3; COMP, cartilage oligomeric matrix protein; ADAMTS-7, A disintegrin and metalloproteinase with thrombospondin motifs 7; FLS, Fibroblast-like synoviocytes; anti-dsDNA, anti-double-stranded DNA antibody; LSC, localized scleroderma; Flt1, Transcription factor Friend leukemia virus integration 1; Tgfri, TGF-β receptor I; TPA, 12-O-tetradecanoylphorbol 13-acetate; IFN-γ, Interferon gamma; IL-17A, interleukin-17A; rPGRN, recombinant human progranulin; GCs, glucocorticoids; COL1, collagen type I; α-SMA, α-smooth muscle actin; Tgfri, TGF-β receptor I; CTGF, connective tissue growth factor; Flt1, Transcription factor Friend leukemia virus integration 1; DSS, dextran sulfate sodium; TNBS, trinitrobenzene sulfonic acid; PGRN-Abs, neutralizing autoantibodies against PGRN; IL-1β, interleukin-1beta; IL-6, Interleukin 6; COX-2, cyclooxygenase-2; iNOS, Inducible nitric oxide synthase; MCP-1, Monocyte chemoattractant protein-1; NOS2, nitric oxide synthase-2; CNS, central nervous system; NAWM, normal appearing white matter; CSF, cerebrospinal fluid; SORT1, sortilin 1; SLPI, secretory leukocyte protease inhibitor. PGRN, Prosaposin; FTLD, frontotemporal lobar degeneration.

Acknowledgments
This research was supported by the National Natural Science Foundation of China. (No. 81274172, 81473267 and 81973637); The National Traditional Chinese Medicine Inheritance and Innovation “Hundreds and Thousands” Talent Project: Young Qihuang Scholar Support Project of the State Administration of Traditional Chinese Medicine in 2020.

Disclosure
The authors report no conflicts of interest in this work.

References


Lan et al


